TY - JOUR
T1 - Management of metastatic urothelial cancer
T2 - The role of surgery as an adjunct to chemotherapy
AU - Svatek, Robert S.
AU - Siefker-Radtke, Arlene
AU - Dinney, Colin P.
PY - 2009
Y1 - 2009
N2 - Metastatic or unresectable disease is identified in approximately 20% of patients presenting with invasive urothelial cancer. In addition, up to 50% of patients will develop metastases following radical cystectomy for clinically localized disease. Multiagent cisplatin-based chemotherapy is considered standard first-line treatment for these patients. Although urothelial cancer is considered a chemosensitive tumour, metastatic disease is associated with poor prognosis and short-term survival. Here, we review the role of a multidisciplinary approach to treating patients with metastatic urothelial cancer.
AB - Metastatic or unresectable disease is identified in approximately 20% of patients presenting with invasive urothelial cancer. In addition, up to 50% of patients will develop metastases following radical cystectomy for clinically localized disease. Multiagent cisplatin-based chemotherapy is considered standard first-line treatment for these patients. Although urothelial cancer is considered a chemosensitive tumour, metastatic disease is associated with poor prognosis and short-term survival. Here, we review the role of a multidisciplinary approach to treating patients with metastatic urothelial cancer.
UR - http://www.scopus.com/inward/record.url?scp=75849127221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75849127221&partnerID=8YFLogxK
M3 - Review article
C2 - 20019991
AN - SCOPUS:75849127221
SN - 1911-6470
VL - 3
SP - S228-S231
JO - Journal of the Canadian Urological Association
JF - Journal of the Canadian Urological Association
IS - 6 SUPPL. 4
ER -